MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the first commercial placement of the REM-I platform at Erasmus Medical Center in Rotterdam. This commercial milestone follows placements of pre-commercial instruments at laboratories in Europe and the U.S. for Beta testing. In addition, the company announced plans to share new data and customer experiences with the REM-I platform at upcoming scientific meetings. These include the Congress of the International Society for the Advancement of Cytometry, CYTO 2024, taking place May 4-8, 2024, in Edinburgh, Scotland and the American Association of Immunologists annual conference, Immunology 2024, taking place May 3-7, 2024, in Chicago, Ill.
“With the full commercial launch of the REM-I platform, we look forward to seeing the broad range of scientific questions our customers tackle with the ability to combine single cell imaging, sorting, and high-dimensional analysis,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer and Deepcell. “We’ve already seen tremendous interest in the REM-I platform and look forward to sharing more data from our platform at AAI and CYTO."
The REM-I platform is a high-dimensional single cell morphology solution which comprises the REM-I benchtop instrument, an AI Foundation Model, and the Axon data suite. By bringing together single cell imaging, sorting, and high-dimensional analysis, the REM-I platform will catalyze new methods of discovery in a wide range of fields including cancer biology, developmental biology, stem cell biology, gene therapy, and functional screening, among others.
“Deepcell’s technology will support our research in onco-cardio and transplantation rejection, enabling us to apply artificial intelligence to study immune and cancer cells and their functions in greater detail,” said Peter van der Spek, Ph.D., Professor, Department of Pathology & Clinical Bioinformatics, Erasmus Medical Center. “Being able to understand cell morphology in this way, rather than using predefined parameters, will enable new discoveries not possible with previous research techniques.”
Deepcell activities at CYTO 2024
Commercial Tutorial
Title: Unveiling the unseen, reimagining biology: Pioneering morpholomics with the REM-I platform
Presentation Date and Time: May 5, 2024, 12:15 - 1:15 p.m.
Location: Room Lowther
Scientific Oral Presentations
Title: Determination of cell viability using high-dimensional morphology analysis
Presentation Date and Time: May 7, 2024, 10:30-11:30 a.m.
Location: Room Sidlaw
Title: Self-supervised deep learning enables label-free high-dimensional morphology profiling of immune cell subtypes
Presentation Date and Time: May 8, 2024, 10:30-11:30 a.m.
Location: Room Moorfoot
Poster Presentation
Poster Title: High-dimensional morphological profiling powered by artificial intelligence enables label-free cellular insight
Presentation Date and Time: May 7, 2024, 6:00-7:00 p.m.
Board Number: 163
The REM-I instrument will be on display and Axon data suite demonstrations will be available throughout the show in booth #20. For more information about activities at CYTO, visit https://deepcell.com/cyto-2024.
Deepcell activities at Immunology 2024
Poster Presentation
Poster Title: Self-supervised deep learning enables label-free, high-dimensional morphology profiling of immune cell types
Presentation Date and Time: May 4, 2024, 11:30 a.m. – 12:45 p.m.
Board Number: B881
Axon data suite demonstrations will be available throughout the show in booth # 665.
For more information on the REM-I platform visit www.deepcell.com/product.
About Deepcell
Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on Linkedin, Twitter, and YouTube.
